As an inhibitor of fibroblast growth factor receptor ( FGFR) - 1, FGFR- 2, FGFR- 3, vascular endothelial growth factor receptor ( VEGFR) - 2, and VEGFR- 3, brivanib can inhibit tumor angiogenesis and growth. Phase Ⅰ and Ⅱ clinical trials have demonstrated the safety and efficacy of brivanib in the treatment of hepatocellular carcinoma ( HCC) . However, one phase Ⅲ, randomized, double-blind, placebo- controlled study showed that the overall survival was not significantly improved in patients receiving brivanib as a second-line therapy for advanced HCC, who had failed treatment with sorafenib, than in those receiving placebo. Another phase Ⅲ, randomized, double- blind, controlled study also showed that the overall survival was not significantly improved in patients receiving brivanib as a first-line therapy for HCC than in those receiving sorafenib. Due to the failure of the two phase Ⅲ studies, two other ongoing phase Ⅲ clinical trials had to be discontinued. Subgroup analysis and prior selection of patients with FGF who might benefit from brivanib may be necessary for further investigation of brivanib in the therapy for HCC.
[1]ALLEN E, WALTERS IB, HANAHAN D.Brivanib, a dual FGF/VEGF inhibitor, is active both first and second line against mouse pancreatic neuroendocrine tumors developing adaptive/evasive resistance to VEGF inhibition[J].Clin Cancer Res, 2011, 17 (16) :5299-5310.
|
[2]AYERS M, FARGNOLI J, LEWIN A, et al.Discovery and validation of biomarkers that respond to treatment with brivanib alaninate, a small-molecule VEGFR-2/FGFR-1 antagonist[J].Cancer Res, 2007, 67 (14) :6899-6906.
|
[3]JONKER DJ, ROSEN LS, SAWYER MB, et al.A phase I study to determine the safety, pharmacokinetics and pharmacodynamics of a dual VEGFR and FGFR inhibitor, brivanib, in patients with advanced or metastatic solid tumors[J].Ann Oncol, 2011, 22 (6) :1413-1419.
|
[4]EL-KHOUEIRY A, LENZ HJ, POSEY J, et al.Effects of hepatic impairment on the pharmacokinetics of brivanib in a phase I, open-label, multidose study in patients with hepatocellular carcinoma and other solid tumors[J].J Hepatol, 2009, 50 (Suppl 1) :288.
|
[5] LLOVET JM, RICCI S, MAZZAFERRO V, et al.Sorafenib in advanced hepatocellular carcinoma[J].N Engl J Med, 2008, 359 (4) :378-390.
|
[6]CHENG AL, KANG YK, CHEN Z, et al.Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma:a phase III randomised, double-blind, placebo-controlled trial[J].Lancet Oncol, 2009, 10 (1) :25-34.
|
[7]PARK JW, FINN RS, KIM JS, et al.Phase II, open-label study of brivanib as first-line therapy in patients with advanced hepatocellular carcinoma[J].Clin Cancer Res, 2011, 17 (7) :1973-1983.
|
[8]FINN RS, KANG YK, MULCAHY M, et al.Phase II, open-label study of brivanib as second-line therapy in patients with advanced hepatocellular carcinoma[J].Clin Cancer Res, 2012, 18 (7) :2090-2098.
|
[9]JOHNSON P, QIN S, PARK JW, et al.Brivanib versus sorafenib as first-lin therapy in patients with unresectable, advanced hepatocellular carcinoma:Results from the phase 3 BRISK-FL study[J].Hepatoloy, 2012, 56 (6) :1519a-1520a.
|
[10]LLOVET JM, DECAENS T, RAOUL JL, et al.Brivanib versus placebo in patients with advanced hepatocellular carcinoma (HCC) who failed or were intolerant to sorafenib:results from the Phase 3BRISK-PS study[J].J Hepatol, 2012, 56 (Suppl) :549.
|
[11]VILLANUEVA A.Rethinking future development of molecular therapies in hepatocellular carcinoma:A bottom-up approach[J].J Hepatol, 2013, 59 (2) :392-395.
|